{"version":"1.0","type":"link","title":"An evaluation of elranatamab for the treatment of myeloma: current evidence for treating relapsed/refractory disease and future directions.","author_name":"Bayly-McCredie E 외","author_url":"https://prs-insight.online/author/Bayly-McCredie%20E","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/88638","thumbnail_width":1200,"thumbnail_height":630}